SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regio...

Full description

Saved in:
Bibliographic Details
Published inViruses Vol. 13; no. 8; p. 1648
Main Authors Popova, Anna Y., Smirnov, Viacheslav S., Andreeva, Elena E., Babura, Elena A., Balakhonov, Sergey V., Bashketova, Natalia S., Bugorkova, Svetlana A., Bulanov, Maxim V., Valeullina, Natalia. N., Vetrov, Viacheslav. V., Goryaev, Dmitriy. V., Detkovskaya, Tatyana N., Ezhlova, Elena B., Zaitseva, Natalia N., Istorik, Olga A., Kovalchuk, Irina. V., Kozlovskikh, Dmitriy N., Kombarova, Svetlana Y., Kurganova, Olga. P., Lomovtsev, Alexander. E., Lukicheva, Lena A., Lyalina, Ludmila V., Melnikova, Albina. A., Mikailova, Olga M., Noskov, Alexei K., Noskova, Ludmila N., Oglezneva, Elena E., Osmolovskaya, Tatyana P., Patyashina, Marina A., Penkovskaya, Natalia A., Samoilova, Lada V., Stepanova, Tatyana F., Trotsenko, Olga E., Totolian, Areg A.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 19.08.2021
MDPI
Subjects
Online AccessGet full text
ISSN1999-4915
1999-4915
DOI10.3390/v13081648

Cover

Loading…
Abstract The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.
AbstractList The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.
The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.
Author Bulanov, Maxim V.
Noskov, Alexei K.
Penkovskaya, Natalia A.
Detkovskaya, Tatyana N.
Smirnov, Viacheslav S.
Vetrov, Viacheslav. V.
Valeullina, Natalia. N.
Melnikova, Albina. A.
Mikailova, Olga M.
Balakhonov, Sergey V.
Popova, Anna Y.
Istorik, Olga A.
Bashketova, Natalia S.
Lukicheva, Lena A.
Stepanova, Tatyana F.
Trotsenko, Olga E.
Lomovtsev, Alexander. E.
Lyalina, Ludmila V.
Noskova, Ludmila N.
Kovalchuk, Irina. V.
Samoilova, Lada V.
Kombarova, Svetlana Y.
Patyashina, Marina A.
Kozlovskikh, Dmitriy N.
Babura, Elena A.
Zaitseva, Natalia N.
Andreeva, Elena E.
Totolian, Areg A.
Kurganova, Olga. P.
Osmolovskaya, Tatyana P.
Bugorkova, Svetlana A.
Ezhlova, Elena B.
Goryaev, Dmitriy. V.
Oglezneva, Elena E.
AuthorAffiliation 29 Khabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia; trotsenko_oe@hniiem.ru
2 Saint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia; vvv-3@bk.ru (V.V.V.); lyalina@pasteurorg.ru (L.V.L.); pasteur@pasteurorg.ru (A.A.T.)
10 Rospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia; goryaev_dv@24.rospotrebnadzor.ru
8 Center for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia; sgm@vladses.vladinfo.ru
14 Rospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia; Kovalchuk_IV@26.rospotrebnadzor.ru
17 Rospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia; info@rospotrebnadzor-amur.ru
21 Rostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia; noskov-epid@mai.ru
1 Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia; anna.popova.00.00@mail.ru (A.Y.P.); ezhlova_eb@rospotrebna
AuthorAffiliation_xml – name: 28 Tyumen Research Institute of Regional Infectious Pathology, 625026 Tyumen, Russia; StepanovaTF@Tniikip.rospotrebnadzor.ru
– name: 18 Rospotrebnadzor Administration in the Tula Region, 300045 Tula, Russia; tula@71.rospotrebnadzor.ru
– name: 24 Rospotrebnadzor Administration in the Krasnodar Territory, 350000 Krasnodar, Russia; gorses@mail.kuban.ru
– name: 13 Rospotrebnadzor Administration in the Leningrad Region, 192029 St. Petersburg, Russia; lenobl@47.rospotrebnadzor.ru
– name: 5 Irkutsk Research Anti-Plague Institute, 664047 Irkutsk, Russia; adm@chumin.irkutsk.ru
– name: 22 Rospotrebnadzor Administration for the Astrakhan Region, 414057 Astrakhan, Russia; tu_rpn@astrakhan.ru
– name: 29 Khabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia; trotsenko_oe@hniiem.ru
– name: 26 Rospotrebnadzor Administration in the Republic of Crimea, 295034 Simferopol, Russia; crimea@82.rospotrebnadzor.ru
– name: 2 Saint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia; vvv-3@bk.ru (V.V.V.); lyalina@pasteurorg.ru (L.V.L.); pasteur@pasteurorg.ru (A.A.T.)
– name: 8 Center for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia; sgm@vladses.vladinfo.ru
– name: 14 Rospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia; Kovalchuk_IV@26.rospotrebnadzor.ru
– name: 11 Rospotrebnadzor Administration in the Primorsky Krai, 690950 Vladivostok, Russia; Detkovskaya_TN@pkrpn.ru
– name: 1 Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia; anna.popova.00.00@mail.ru (A.Y.P.); ezhlova_eb@rospotrebnadzor.ru (E.B.E.); melnikova_aa@rospotrebnadzor.ru (A.A.M.)
– name: 7 Russian Research Anti-Plague Institute “Microbe”, 410005 Saratov, Russia; bugorkova29@mail.ru
– name: 21 Rostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia; noskov-epid@mai.ru
– name: 25 Rospotrebnadzor Administration in the Republic of Tatarstan, 420111 Kazan, Russia; org@16.rospotrebnadzor.ru
– name: 12 Nizhny Novgorod I. N. Blokhina Research Institute of Epidemiology and Microbiology, 603950 Nizhny Novgorod, Russia; vtashca@mail.ru
– name: 27 Rospotrebnadzor Administration in the Novosibirsk Region, 630132 Novosibirsk, Russia; epid@54rospotrebnadzor.ru
– name: 9 Rospotrebnadzor Administration in the Chelyabinsk Region, 454091 Chelyabinsk, Russia; ValeullinaNN@chel.surpet.ru
– name: 20 Rospotrebnadzor Administration in the Moscow Region, 141014 Mytishchi, Moscow Region, Russia; org@50.rospotrebnadzor.ru
– name: 3 Rospotrebnadzor Administration in Moscow, 129626 Moscow, Russia; uprav@77.rospotrebnadzor.ru
– name: 10 Rospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia; goryaev_dv@24.rospotrebnadzor.ru
– name: 6 Rospotrebnadzor Administration in St. Petersburg, 191025 St. Petersburg, Russia; nbashketova@gmail.com
– name: 17 Rospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia; info@rospotrebnadzor-amur.ru
– name: 4 Rospotrebnadzor Administration in the Kaliningrad Region, 236040 Kaliningrad, Russia; elena_babura@mail.ru
– name: 19 Rospotrebnadzor Administration in the Murmansk Region, 183038 Murmansk, Russia; lukichevalena@icloud.com
– name: 23 Rospotrebnadzor Administration in the Belgorod Region, 308023 Belgorod, Russia; orgotd@31rospotrebnadzor.ru
– name: 15 Rospotrebnadzor Administration in the Sverdlovsk Region, 620078 Yekaterinburg, Russia; Kozlovskih_DN@66rospotrebnadzor.ru
– name: 16 G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, 125212 Moscow, Russia; kombarova311@bk.ru
Author_xml – sequence: 1
  givenname: Anna Y.
  surname: Popova
  fullname: Popova, Anna Y.
– sequence: 2
  givenname: Viacheslav S.
  orcidid: 0000-0002-2723-1496
  surname: Smirnov
  fullname: Smirnov, Viacheslav S.
– sequence: 3
  givenname: Elena E.
  surname: Andreeva
  fullname: Andreeva, Elena E.
– sequence: 4
  givenname: Elena A.
  surname: Babura
  fullname: Babura, Elena A.
– sequence: 5
  givenname: Sergey V.
  surname: Balakhonov
  fullname: Balakhonov, Sergey V.
– sequence: 6
  givenname: Natalia S.
  surname: Bashketova
  fullname: Bashketova, Natalia S.
– sequence: 7
  givenname: Svetlana A.
  surname: Bugorkova
  fullname: Bugorkova, Svetlana A.
– sequence: 8
  givenname: Maxim V.
  surname: Bulanov
  fullname: Bulanov, Maxim V.
– sequence: 9
  givenname: Natalia. N.
  surname: Valeullina
  fullname: Valeullina, Natalia. N.
– sequence: 10
  givenname: Viacheslav. V.
  surname: Vetrov
  fullname: Vetrov, Viacheslav. V.
– sequence: 11
  givenname: Dmitriy. V.
  surname: Goryaev
  fullname: Goryaev, Dmitriy. V.
– sequence: 12
  givenname: Tatyana N.
  surname: Detkovskaya
  fullname: Detkovskaya, Tatyana N.
– sequence: 13
  givenname: Elena B.
  surname: Ezhlova
  fullname: Ezhlova, Elena B.
– sequence: 14
  givenname: Natalia N.
  surname: Zaitseva
  fullname: Zaitseva, Natalia N.
– sequence: 15
  givenname: Olga A.
  surname: Istorik
  fullname: Istorik, Olga A.
– sequence: 16
  givenname: Irina. V.
  surname: Kovalchuk
  fullname: Kovalchuk, Irina. V.
– sequence: 17
  givenname: Dmitriy N.
  surname: Kozlovskikh
  fullname: Kozlovskikh, Dmitriy N.
– sequence: 18
  givenname: Svetlana Y.
  surname: Kombarova
  fullname: Kombarova, Svetlana Y.
– sequence: 19
  givenname: Olga. P.
  surname: Kurganova
  fullname: Kurganova, Olga. P.
– sequence: 20
  givenname: Alexander. E.
  surname: Lomovtsev
  fullname: Lomovtsev, Alexander. E.
– sequence: 21
  givenname: Lena A.
  surname: Lukicheva
  fullname: Lukicheva, Lena A.
– sequence: 22
  givenname: Ludmila V.
  surname: Lyalina
  fullname: Lyalina, Ludmila V.
– sequence: 23
  givenname: Albina. A.
  surname: Melnikova
  fullname: Melnikova, Albina. A.
– sequence: 24
  givenname: Olga M.
  surname: Mikailova
  fullname: Mikailova, Olga M.
– sequence: 25
  givenname: Alexei K.
  surname: Noskov
  fullname: Noskov, Alexei K.
– sequence: 26
  givenname: Ludmila N.
  surname: Noskova
  fullname: Noskova, Ludmila N.
– sequence: 27
  givenname: Elena E.
  surname: Oglezneva
  fullname: Oglezneva, Elena E.
– sequence: 28
  givenname: Tatyana P.
  surname: Osmolovskaya
  fullname: Osmolovskaya, Tatyana P.
– sequence: 29
  givenname: Marina A.
  surname: Patyashina
  fullname: Patyashina, Marina A.
– sequence: 30
  givenname: Natalia A.
  surname: Penkovskaya
  fullname: Penkovskaya, Natalia A.
– sequence: 31
  givenname: Lada V.
  surname: Samoilova
  fullname: Samoilova, Lada V.
– sequence: 32
  givenname: Tatyana F.
  surname: Stepanova
  fullname: Stepanova, Tatyana F.
– sequence: 33
  givenname: Olga E.
  surname: Trotsenko
  fullname: Trotsenko, Olga E.
– sequence: 34
  givenname: Areg A.
  surname: Totolian
  fullname: Totolian, Areg A.
BookMark eNqFkktrGzEURoeS0jzaRf_BQDftYhq9ZW0KwX0ZAglxm0U34lq648iMJUeaMfTfd2yH0IRCVxK6Rwd9uve0OoopYlW9peQj54acbyknE6rE5EV1Qo0xjTBUHv21P65OS1kRopQh-lV1zIWQTFJ2Uv2aX9zMm2m6bVg9x5w2GbfQYXRYz_s8uH7IWKe27u-wvhlKCRDr67QZOuhDirUfcojLfXV6dTv73FBTX0P0uA7udfWyha7gm4f1rPr59cuP6ffm8urbbHpx2TihTd8gKFggRUolNdgiR6Wdb4lErg2DVjtUjIL3oLUHtpBG0IlnHluNqpWMn1Wzg9cnWNlNDmvIv22CYPcHKS8t5D64Dq03SnLDFDhGhPdsIrkGQqH1YkEoktH16eDaDIs1eoexz9A9kT6txHBnl2lrJ4IwLekoeP8gyOl-wNLbdSgOuw4ipqFYprjSQjGp_o9KpYgYe7iL-O4ZukpDjuOv7iipxzRmJ_xwoFxOpWRsH99Nid0Nin0clJE9f8a60O97OsYK3T9u_AF-ub6t
CitedBy_id crossref_primary_10_1080_23744235_2023_2179660
crossref_primary_10_31631_2073_3046_2024_23_4_12_22
crossref_primary_10_15789_1563_0625_PVI_2457
crossref_primary_10_1016_j_abst_2025_03_001
crossref_primary_10_3390_v15102014
crossref_primary_10_3390_vaccines13030249
crossref_primary_10_51350_zdravkg_2023_11_61_001
crossref_primary_10_3390_ijerph19042263
crossref_primary_10_31631_2073_3046_2022_21_1_81_91
crossref_primary_10_15789_2220_7619_MFA_1770
crossref_primary_10_3390_v15112181
crossref_primary_10_4103_OJMR_OJMR_12_23
crossref_primary_10_1007_s12519_022_00617_2
crossref_primary_10_1093_ofid_ofad614
crossref_primary_10_3390_v14050913
crossref_primary_10_15789_2220_7619_HIT_1798
crossref_primary_10_7189_jogh_13_06004
crossref_primary_10_15789_1563_0625_PIT_2867
crossref_primary_10_1016_j_envres_2022_114655
crossref_primary_10_3390_v14050941
crossref_primary_10_22625_2072_6732_2021_13_4_79_89
crossref_primary_10_21886_2219_8075_2022_13_2_199_216
crossref_primary_10_1371_journal_pone_0311287
crossref_primary_10_15789_1563_0625_MOF_2490
Cites_doi 10.21055/0370-1069-2020-3-114-123
10.1016/S0140-6736(21)00183-5
10.1016/j.medj.2020.10.003
10.1172/jci.insight.142386
10.21055/0370-1069-2020-3-124-130
10.1126/science.abj3858
10.36233/0372-9311-92
10.3389/fcell.2020.547314
10.1016/j.cell.2020.09.038
10.20953/1729-9225-2020-4-17-26
10.1126/science.abe1107
10.1001/jamanetworkopen.2021.4302
10.1001/jama.2020.8707
10.3390/v13010029
10.3201/eid2705.204365
10.1016/j.jinf.2020.03.027
10.1007/s15010-021-01629-2
10.3201/eid2609.201840
10.24110/0031-403X-2021-100-3-97-106
10.7554/eLife.63537
10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
10.1001/jama.2020.8279
10.3390/vaccines8020236
10.1002/jnr.24752
10.1016/j.xcrm.2021.100313
10.1016/S0140-6736(21)00238-5
10.1136/bmjopen-2020-045425
10.2807/1560-7917.ES.2020.25.16.2000421
10.22625/2072-6732-2020-12-5-62-71
10.36233/0372-9311-2020-97-6-2
10.4103/ijmr.IJMR_977_20
10.21055/0370-1069-2020-3-106-113
10.1016/j.jcv.2020.104683
10.1001/jamainternmed.2020.4130
10.1126/science.abc6810
10.1016/j.immuni.2020.04.012
10.1101/2020.07.18.20155374
10.1016/j.jhin.2020.11.008
10.1016/j.pcl.2020.07.014
10.1016/j.immuni.2020.05.002
10.3389/fped.2021.619738
10.1038/s41591-020-0949-6
10.1016/j.cmi.2020.10.020
10.3389/fimmu.2020.586781
10.3389/fimmu.2021.631139
10.1002/ppul.24981
10.3346/jkms.2020.35.e333
10.1038/s41591-020-0965-6
10.1016/S1473-3099(20)30858-6
10.5694/mja2.50940
10.1002/cti2.1136
10.1101/2020.04.25.20079103
10.20953/1729-9225-2020-4-8-16
10.1038/s41581-020-00357-4
10.1038/s41591-020-0913-5
10.36233/0372-9311-2020-97-5-1
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7U9
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
7S9
L.6
5PM
DOA
DOI 10.3390/v13081648
DatabaseName CrossRef
ProQuest Central (Corporate)
Virology and AIDS Abstracts
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection (ProQuest)
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA

Publicly Available Content Database
MEDLINE - Academic
CrossRef

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1999-4915
ExternalDocumentID oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0
PMC8402751
10_3390_v13081648
GeographicLocations Russia
GeographicLocations_xml – name: Russia
GroupedDBID ---
2WC
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACUHS
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
E3Z
EBD
ESX
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M48
M7P
MODMG
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
TR2
TUS
UKHRP
3V.
7U9
7XB
8FK
AZQEC
COVID
DWQXO
GNUQQ
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
7S9
L.6
5PM
PUEGO
ID FETCH-LOGICAL-c479t-ea6abe1e11519efe3e67cdf05e3792af7ce621adda77da2b59418d2def7e6f523
IEDL.DBID DOA
ISSN 1999-4915
IngestDate Wed Aug 27 01:31:08 EDT 2025
Thu Aug 21 18:34:45 EDT 2025
Fri Jul 11 02:27:19 EDT 2025
Mon Jul 21 09:49:37 EDT 2025
Fri Jul 25 09:59:16 EDT 2025
Tue Jul 01 02:48:26 EDT 2025
Thu Apr 24 22:58:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c479t-ea6abe1e11519efe3e67cdf05e3792af7ce621adda77da2b59418d2def7e6f523
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2723-1496
OpenAccessLink https://doaj.org/article/d9653926ac204dd28537a01afd4b01e0
PMID 34452512
PQID 2565720496
PQPubID 2032319
ParticipantIDs doaj_primary_oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8402751
proquest_miscellaneous_2636746256
proquest_miscellaneous_2566041992
proquest_journals_2565720496
crossref_primary_10_3390_v13081648
crossref_citationtrail_10_3390_v13081648
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210819
PublicationDateYYYYMMDD 2021-08-19
PublicationDate_xml – month: 8
  year: 2021
  text: 20210819
  day: 19
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Viruses
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Popova (ref_29) 2020; 4
ref_50
Kwok (ref_45) 2020; 80
Popova (ref_23) 2020; 3
Popova (ref_28) 2020; 18
Popova (ref_24) 2020; 97
Popova (ref_22) 2021; 100
Shiakolas (ref_42) 2021; 2
ref_53
Popova (ref_31) 2021; 11
Hippich (ref_44) 2021; 2
Hou (ref_49) 2020; 9
ref_16
ref_15
Vabret (ref_8) 2020; 52
Grant (ref_60) 2021; 11
Kuttiatt (ref_13) 2020; 152
Williams (ref_43) 2020; 52
Popova (ref_17) 2021; 11
Yang (ref_36) 2021; 4
Moderbacher (ref_39) 2020; 183
ref_67
Uversky (ref_3) 2020; 99
Balicer (ref_10) 2021; 37
Jeremijenko (ref_62) 2021; 27
Britton (ref_70) 2020; 369
Perico (ref_2) 2020; 17
Amanat (ref_12) 2020; 26
Goyal (ref_52) 2021; 10
Grzhibovsky (ref_21) 2008; 5
Pujari (ref_5) 2020; 12
Popova (ref_32) 2021; 13
Sood (ref_35) 2020; 323
Popova (ref_26) 2020; 12
Reicher (ref_69) 2021; 2021
Bunyavanich (ref_40) 2020; 323
Randolph (ref_7) 2020; 52
Poustchi (ref_63) 2021; 21
Popova (ref_33) 2020; 97
Newcombe (ref_34) 1998; 17
Han (ref_37) 2021; 9
Havers (ref_64) 2020; 180
Kuznik (ref_38) 2020; 33
Long (ref_55) 2020; 26
Popova (ref_18) 2020; 3
Perera (ref_58) 2020; 25
Chen (ref_47) 2021; 9
Tsabouri (ref_68) 2021; 68
Gidding (ref_66) 2021; 214
Popova (ref_27) 2020; 18
Fialkowski (ref_51) 2020; 55
Popova (ref_19) 2020; 3
Vignesh (ref_11) 2020; 11
Agresti (ref_20) 1998; 52
Khoshchehreh (ref_56) 2020; 133
Rostami (ref_9) 2020; 27
Jeong (ref_54) 2020; 35
Popova (ref_25) 2020; 4
ref_41
Triggle (ref_48) 2021; 12
Galanis (ref_46) 2021; 108
ref_1
He (ref_14) 2021; 397
Popova (ref_30) 2021; 98
Xia (ref_59) 2020; 8
McAndrews (ref_57) 2020; 5
Xu (ref_61) 2020; 26
ref_4
Sabino (ref_65) 2021; 397
ref_6
References_xml – volume: 3
  start-page: 114
  year: 2020
  ident: ref_18
  article-title: Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic
  publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii]
  doi: 10.21055/0370-1069-2020-3-114-123
– volume: 397
  start-page: 452
  year: 2021
  ident: ref_65
  article-title: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00183-5
– volume: 2
  start-page: 149
  year: 2021
  ident: ref_44
  article-title: A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children
  publication-title: Med.
  doi: 10.1016/j.medj.2020.10.003
– volume: 5
  start-page: e142386
  year: 2020
  ident: ref_57
  article-title: Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.142386
– volume: 3
  start-page: 124
  year: 2020
  ident: ref_19
  article-title: Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic
  publication-title: Probl. Osob. Opasnykh Infektsii [Probl. Part. Danger. Infect.]
  doi: 10.21055/0370-1069-2020-3-124-130
– volume: 37
  start-page: 663
  year: 2021
  ident: ref_10
  article-title: Israel’s COVID-19 endgame
  publication-title: Science
  doi: 10.1126/science.abj3858
– volume: 98
  start-page: 7
  year: 2021
  ident: ref_30
  article-title: The seroprevalence of SARS-CoV-2 among residents of the Khabarovsk Krai during the COVID-19 epidemic
  publication-title: J. Microbiol. Epidemiol. Immunobiol. [Zhurnal Mikrobiol. Èpidemiologii I Immunobiol.]
  doi: 10.36233/0372-9311-92
– ident: ref_16
– volume: 8
  start-page: 547314
  year: 2020
  ident: ref_59
  article-title: How to Understand “Herd Immunity” in COVID-19 Pandemic
  publication-title: Front. Cell. Dev. Biol.
  doi: 10.3389/fcell.2020.547314
– volume: 13
  start-page: 17
  year: 2021
  ident: ref_32
  article-title: Humoral immunity to SARS-CoV-2 among the population of Murmansk region amid COVID-19 epidemic
  publication-title: HIV Infect. Immunosuppr.
– volume: 183
  start-page: 996
  year: 2020
  ident: ref_39
  article-title: Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.038
– volume: 9
  start-page: e598
  year: 2021
  ident: ref_47
  article-title: Serological evidence of human infection with SARS-CoV-2: A systematic review and meta-analysis Lancet Glob
  publication-title: Health
– volume: 18
  start-page: 17
  year: 2020
  ident: ref_28
  article-title: The structure of seroprevalence to the SARS-CoV-2 virus among residents of the Moscow Region during the period of epidemic incidence of COVID-19
  publication-title: Infekc. Bolezn. [Infect. Dis.]
  doi: 10.20953/1729-9225-2020-4-17-26
– ident: ref_41
  doi: 10.1126/science.abe1107
– volume: 4
  start-page: e214302
  year: 2021
  ident: ref_36
  article-title: Association of Age With SARS-CoV-2 Antibody Response
  publication-title: JAMA Netw Open.
  doi: 10.1001/jamanetworkopen.2021.4302
– ident: ref_1
– volume: 323
  start-page: 2427
  year: 2020
  ident: ref_40
  article-title: Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults
  publication-title: JAMA
  doi: 10.1001/jama.2020.8707
– ident: ref_4
  doi: 10.3390/v13010029
– volume: 27
  start-page: 1343
  year: 2021
  ident: ref_62
  article-title: Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2705.204365
– volume: 80
  start-page: e32
  year: 2020
  ident: ref_45
  article-title: Herd immunity—Estimating the level required to halt the COVID-19 epidemics in affected countries
  publication-title: J. Infect.
  doi: 10.1016/j.jinf.2020.03.027
– ident: ref_67
  doi: 10.1007/s15010-021-01629-2
– ident: ref_15
  doi: 10.3201/eid2609.201840
– volume: 100
  start-page: 97
  year: 2021
  ident: ref_22
  article-title: Peculiarities of seroprevalence to nucleocapsid SARS-CoV-2 in children during the 2020 COVID-19 epidemic
  publication-title: Pediatric
  doi: 10.24110/0031-403X-2021-100-3-97-106
– volume: 10
  start-page: e63537
  year: 2021
  ident: ref_52
  article-title: Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events
  publication-title: eLife
  doi: 10.7554/eLife.63537
– volume: 17
  start-page: 857
  year: 1998
  ident: ref_34
  article-title: Two-sided confidence intervals for the single proportion: Comparison of seven methods
  publication-title: Stat. Med.
  doi: 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
– volume: 4
  start-page: 117
  year: 2020
  ident: ref_25
  article-title: Assessment of Population Immunity to SARS-CoV-2 Virus in the Rostov Region
  publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii]
– volume: 52
  start-page: 119
  year: 1998
  ident: ref_20
  article-title: Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions
  publication-title: Am. Stat.
– volume: 323
  start-page: 2425
  year: 2020
  ident: ref_35
  article-title: Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020
  publication-title: JAMA
  doi: 10.1001/jama.2020.8279
– ident: ref_6
  doi: 10.3390/vaccines8020236
– volume: 99
  start-page: 750
  year: 2020
  ident: ref_3
  article-title: Severe acute respiratory syndrome coronavirus 2 infection reaches the human nervous system: How?
  publication-title: J. Neurosci. Res.
  doi: 10.1002/jnr.24752
– volume: 11
  start-page: 29
  year: 2021
  ident: ref_31
  article-title: Analysis of SARS-CoV-2 seroprevalence among the population of the Vladimir Region during the COVID-19 epidemic. Epidemiology and infectious diseases
  publication-title: Curr. Items
– volume: 2
  start-page: 100313
  year: 2021
  ident: ref_42
  article-title: Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2021.100313
– volume: 397
  start-page: 1075
  year: 2021
  ident: ref_14
  article-title: Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00238-5
– volume: 11
  start-page: e045425
  year: 2021
  ident: ref_60
  article-title: SARS-CoV-2 population-based seroprevalence studies in Europe: A scoping review
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2020-045425
– volume: 25
  start-page: 2000421
  year: 2020
  ident: ref_58
  article-title: Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
  publication-title: Euro Surveill.
  doi: 10.2807/1560-7917.ES.2020.25.16.2000421
– volume: 12
  start-page: 62
  year: 2020
  ident: ref_26
  article-title: Population immunity to SARS-CoV-2 of the population of the Kaliningrad region during the epidemic season of COVID-19
  publication-title: J. Infectology [Zhurnal Infektologii]
  doi: 10.22625/2072-6732-2020-12-5-62-71
– volume: 97
  start-page: 518
  year: 2020
  ident: ref_33
  article-title: Distribution of SARS-CoV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period
  publication-title: J. Microbiol. Epidemiol. Immunobiol. [Zhurnal Mikrobiol. Èpidemiologii I Immunobiologii]
  doi: 10.36233/0372-9311-2020-97-6-2
– volume: 152
  start-page: 21
  year: 2020
  ident: ref_13
  article-title: Coronavirus disease 2019 in children: Clinical & epidemiological implications
  publication-title: Indian J. Med. Res.
  doi: 10.4103/ijmr.IJMR_977_20
– volume: 33
  start-page: 1032
  year: 2020
  ident: ref_38
  article-title: Features of pathogenesis and COVID-19 course for the elderly and old age
  publication-title: Adv. Geront.
– volume: 3
  start-page: 106
  year: 2020
  ident: ref_23
  article-title: Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak
  publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii]
  doi: 10.21055/0370-1069-2020-3-106-113
– volume: 2021
  start-page: 1
  year: 2021
  ident: ref_69
  article-title: Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
  publication-title: Eur. J. Epidemiol.
– volume: 12
  start-page: e10480
  year: 2020
  ident: ref_5
  article-title: Therapeutic Options for COVID-19: A Review
  publication-title: Cureus
– volume: 133
  start-page: 104683
  year: 2020
  ident: ref_56
  article-title: A needle in the haystack? Assessing the significance of envelope (E) gene-negative, nucleocapsid (N2) gene-positive SARS-CoV-2 detection by the Cepheid Xpert Xpress SARS-COV-2 assay
  publication-title: J. Clin. Virol.
  doi: 10.1016/j.jcv.2020.104683
– volume: 180
  start-page: 1576
  year: 2020
  ident: ref_64
  article-title: Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23 May 12, 2020
  publication-title: JAMA Intern. Med.
  doi: 10.1001/jamainternmed.2020.4130
– volume: 4
  start-page: 106
  year: 2020
  ident: ref_29
  article-title: Characteristics of the Herd Immunity to SARS-CoV-2 in Residents of the Saratov Region under COVID-19 Epidemic
  publication-title: Probl. Part. Danger. Infect. [Probl. Osob. Opasnykh Infektsii]
  doi: 10.21055/0370-1069-2020-3-106-113
– volume: 369
  start-page: 846
  year: 2020
  ident: ref_70
  article-title: A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abc6810
– volume: 52
  start-page: 737
  year: 2020
  ident: ref_7
  article-title: Herd Immunity: Understanding COVID-19
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.04.012
– ident: ref_50
  doi: 10.1101/2020.07.18.20155374
– volume: 5
  start-page: 57
  year: 2008
  ident: ref_21
  article-title: Confidence intervals for frequencies and beats
  publication-title: Hum. Ecol.
– volume: 108
  start-page: 120
  year: 2021
  ident: ref_46
  article-title: Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: A systematic review and meta-analysis
  publication-title: J. Hosp. Infect.
  doi: 10.1016/j.jhin.2020.11.008
– volume: 68
  start-page: 321
  year: 2021
  ident: ref_68
  article-title: Risk Factors for Severity in Children with Coronavirus Disease 2019. A Comprehensive Literature Review
  publication-title: Pediatr. Clin. N. Am.
  doi: 10.1016/j.pcl.2020.07.014
– volume: 52
  start-page: 910
  year: 2020
  ident: ref_8
  article-title: The Sinai Immunology Review Project. Immunology of COVID-19: Current state of the science
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.05.002
– volume: 9
  start-page: 619738
  year: 2021
  ident: ref_37
  article-title: Distinct Characteristics of COVID-19 Infection in Children
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2021.619738
– volume: 52
  start-page: 801
  year: 2020
  ident: ref_43
  article-title: SARS-CoV-2 in children: Spectrum of disease, transmission and immunopathological underpinnings
  publication-title: Pathol.
– volume: 26
  start-page: 1193
  year: 2020
  ident: ref_61
  article-title: Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0949-6
– volume: 27
  start-page: 331
  year: 2020
  ident: ref_9
  article-title: SARS-CoV-2 seroprevalence worldwide: A systematic review and meta-analysis
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2020.10.020
– volume: 11
  start-page: 586781
  year: 2020
  ident: ref_11
  article-title: Is Herd Immunity Against SARS-CoV-2 a Silver Lining?
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.586781
– volume: 11
  start-page: 297
  year: 2021
  ident: ref_17
  article-title: Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation
  publication-title: Russ. J. Infect. Immun. [Infektsiya I Immun.]
– volume: 12
  start-page: 631139
  year: 2021
  ident: ref_48
  article-title: A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.631139
– volume: 55
  start-page: 2556
  year: 2020
  ident: ref_51
  article-title: Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection
  publication-title: Pediatric Pulmonol.
  doi: 10.1002/ppul.24981
– volume: 35
  start-page: e333
  year: 2020
  ident: ref_54
  article-title: Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up
  publication-title: J. Korean Med. Sci.
  doi: 10.3346/jkms.2020.35.e333
– volume: 26
  start-page: 1200
  year: 2020
  ident: ref_55
  article-title: Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0965-6
– volume: 21
  start-page: 473
  year: 2021
  ident: ref_63
  article-title: SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(20)30858-6
– volume: 214
  start-page: 179
  year: 2021
  ident: ref_66
  article-title: Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020
  publication-title: Med. J. Aust.
  doi: 10.5694/mja2.50940
– volume: 9
  start-page: e01136
  year: 2020
  ident: ref_49
  article-title: Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
  publication-title: Clin. Transl. Immunol.
  doi: 10.1002/cti2.1136
– ident: ref_53
  doi: 10.1101/2020.04.25.20079103
– volume: 18
  start-page: 8
  year: 2020
  ident: ref_27
  article-title: Collective immunity to SARS-CoV-2 of Moscow residents during the COVID-19 epidemic period
  publication-title: Infekc. Bolezn. [Infect. Dis.]
  doi: 10.20953/1729-9225-2020-4-8-16
– volume: 17
  start-page: 46
  year: 2020
  ident: ref_2
  article-title: Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
  publication-title: Nat. Rev. Nephrol.
  doi: 10.1038/s41581-020-00357-4
– volume: 26
  start-page: 1033
  year: 2020
  ident: ref_12
  article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0913-5
– volume: 97
  start-page: 392
  year: 2020
  ident: ref_24
  article-title: Distribution of SARS-CoV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period
  publication-title: J. Microbiol. Epidemiol. Immunobiol. {Zhurnal Mikrobiol. Èpidemiologii I Immunobiol.]
  doi: 10.36233/0372-9311-2020-97-5-1
SSID ssj0066907
Score 2.3925776
Snippet The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1648
SubjectTerms Adaptive immunity
Age
Antibodies
antigens
Asymptomatic
asymptomatic form
Biotechnology
cohort studies
Coronaviruses
COVID-19
COVID-19 infection
COVID-19 vaccines
Disease transmission
Herd immunity
Immunoglobulin G
Infections
Influenza
Medical research
Morbidity
Mortality
nucleocapsid
Nucleocapsids
pandemic
Pandemics
Participation
Pathogens
Population
Regions
Russia
SARS-CoV-2
Serology
seroprevalence
Severe acute respiratory syndrome coronavirus 2
Volunteers
SummonAdditionalLinks – databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3faxQxEA5aEXwp_sTTKlF88CV0k80mmyepp6UKaunZcviyJJtJLehu2-sJ_vfO7O6tLkhfN8MSJjOT-ZLJN4y9yp0ppZUgfBm00NrnImQuEzG3PqW8xqBI750_fTYHx_rjslgOB26roaxyExO7QB3bms7IdxXdzynMZ82b8wtBXaPodnVooXGT3SLqMgJfdjkCLkPIr2cTyhHa7_7CeF0iPCgne1BH1T_JL6fVkf9sN_t32faQJ_K9fmHvsRvQ3Ge3-86Rvx-wb4u9o4WYtydCcXR3amWCJkNeyhcdI-z6EnibOKZ3_Gi9opeS_HDs1cX7x4nd6PzLyYd3Qjp-SMfJP8_qh-x4__3X-YEY2iSIWlt3JcAbH0AC5nbSQYIcjK1jygrIrVM-2RqMkhjHvLXRq1A4LcuoIiQLJiEQfcS2mraBx4ybmJzWhYplAF1oHTCp1XWogwfpla9n7PVGcVU9cIhTK4sfFWIJ0nE16njGXo6i5z1xxv-E3pL2RwHiuu4-tJen1eA6VXREn6sMkUnqGBUmGNZn0qeoQyYhm7GdzdpVgwOuqr_mMmMvxmF0HboP8Q20607GZJrqb6-RMbmxGkEi_sdO7GIy6elIc_a9I-pG8KxsIZ9cP8Gn7I6iQhni2XU7bAutBJ5hpnMVnnfm_AdoBAAc
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVKERIXxKdYKMggDlwMsePY8QGhslAVpELVZauKS2THY6hUknbbRfTfM5PNRkSqOHFdj6LdyYz93tp-j7EXuTOltBKEL4MWWvtchMxlIubWp5TXOCnSfee9z2Z3rj8dFUcbbO2x2Sfw_EpqR35S88XJq99nl2-x4d8Q40TK_voXzsMlwv7yGruOC5IlB4c9PWwmGCKAK1GhcfhoKeoU-0cwc3xI8q9VZ-c2u9XDRb69er932AY0d9mNlYHk5T32bbZ9MBPT9lAojl1PjiZYOdSsfNYJwy4XwNvEEeXxg-U5XZjk-4NlF1_dUexGp18OP74X0vF9-lf553F9n813Pnyd7oreLUHU2roLAd74ABIQ4kkHCXIwto4pKyC3TvlkazBK4nTmrY1ehcJpWUYVIVkwCfnoA7bZtA08ZNzE5LQuVCwD6ELrgNhW16EOHqRXvp6wl-vEVXUvJU6OFicVUgrKcTXkeMKeD6GnK_2Mq4LeUfaHAJK87j5oF9-rvoOq6EhFVxnSlNQxKsQZ1mfSp6hDJiGbsK31u6vWZVQp2tXFeGcm7NkwjB1E2yK-gXbZxZhM0zHcf8SY3FiNXBGfY0d1MfrS45Hm-Een140cWtlCPvofv_Ixu6noVA2J8rottom1BE8QFl2Ep13R_wHL_Q5L
  priority: 102
  providerName: Scholars Portal
Title SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic
URI https://www.proquest.com/docview/2565720496
https://www.proquest.com/docview/2566041992
https://www.proquest.com/docview/2636746256
https://pubmed.ncbi.nlm.nih.gov/PMC8402751
https://doaj.org/article/d9653926ac204dd28537a01afd4b01e0
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgCIkL4lMslJVBHLhYjR3Hjo_t0lKQWla7tFpxiex4rFaCLKJdJP49M0k2aiQEFy4-xKPImfF45sX2G8be5M6U0koQvgxaaO1zETKXiZhbn1Je46JI951PTs3xmf64KlY3Sn3RmbCOHrhT3F50RJ6qDFEJ6hgVhhfrM-lT1CGT0KJ1jHlbMNWtwYYwX8cjlCOo3_uJK3WJwKAcRZ-WpH-UWY7PRd4INEcP2P0-Q-T73cgeslvQPGJ3u5qRvx6zL8v9xVLM1udCcXR0KmKCk4X8ky9bLtjND-DrxDGx44vNFd2R5POhShfvriW2vbNP5x_eCen4nH4kf7usn7Czo8PPs2PRF0gQtbbuWoA3PoAEzOqkgwQ5GFvHlBWQW6d8sjUYJXEF89ZGr0LhtCyjipAsmIQQ9CnbadYNPGPcxOS0LlQsA-hC64DprK5DHTxIr3w9YW-3iqvqnj2cilh8rRBFkI6rQccT9noQ_d5RZvxJ6IC0PwgQy3X7AG1f9bav_mX7Cdvd2q7qXe-qUrSRi_LOTNiroRudhnZCfAPrTStjMk0nb_8iY3JjNcJDfI8dzYvRoMc9zeVFS9GNsFnZQj7_H1_5gt1TdJCGeHjdLtvBuQQvMRO6DlN2267slN05ODydL6atC2D7fiWxPdHlb-W9DHI
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgQXxFMsFDAIJC5WY8ex4wNCZUu1Sx9U3bZacQmO7UAlSEq3C-qf4jcykxdEQr31Go8iazxPe-YbQl7GRqVc88BsmksmpY1ZHpmI-VjboogdGEXsd97dU5Mj-WGezFfI764XBssqO5tYG2pfObwjXxf4PicgnlVvT38wnBqFr6vdCI1GLLbDxS9I2RZvpptwvq-E2Hp_OJ6wdqoAc1KbcxassnngAUIhbkIR4qC080WUhFgbYQvtghIc1N5q7a3IEyN56oUPhQ6qSBDoAEz-NXC8EZYQ6nmf4CnMNBv0ojg20fpP8A8ppCPpwOfVowEG8eywGvMf97Z1m9xq41K60QjSHbISyrvkejOp8uIe-TTbOJixcXXMBAXzgqNTQETRKtBZjUC7PAu0KiiEk_RgucDOTLrfzwajTTNkvTr-eDzdZNzQfby-_n7i7pOjK2HgA7JaVmV4SKjyhZEyET7Ng0ykzCGIli53uQ3cCutG5HXHuMy1mOU4OuNbBrkL8jjreTwiL3rS0wao439E75D7PQFia9cfqrMvWauqmTcI1ysUgldK7wUENNpG3BZe5hEP0YisdWeXtQq_yP6K54g875dBVfH9xZahWtY0KpJY73sJjYqVlpCUwn_0QC4Gmx6ulCdfa2BwSNaFTvijyzf4jNyYHO7uZDvTve3H5KbAIh3E-DVrZBUkJjyBKOs8f1qLNiWfr1qX_gCbyz93
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIRAviE9RGGAQSLxYjR3Hjh8QGi3VymBUK5uqvQQntmESJGNdQfvX-Ou4S9JAJLS3vcanyDrfp333O0Kex0alXHPPbJpLJqWNWR6ZiLlY2xDiAowi9jt_2FM7B_LdIllskN_rXhgsq1zbxNpQu6rAO_KhwPc5AfGsGoa2LGI2nrw--cFwghS-tK7HaTQisuvPf0H6tnw1HcNZvxBi8vbTaIe1EwZYIbU5Y94qm3vuISzixgcfe6ULF6LEx9oIG3ThleBgAqzWzoo8MZKnTjgftFchQdADMP9XdAxuE3RJL7pkT2HW2SAZxbGJhj_BV6SQmqQ9_1ePCejFtv3KzH9c3eQmudHGqHS7EapbZMOXt8nVZmrl-R1yNN_en7NRdcgEBVODY1RAXNFC0HmNRrs69bQKFEJLur9aYpcmnXVzwmjTGFmvjj4eTseMGzrDq-zvx8VdcnApDLxHNsuq9PcJVS4YKRPh0tzLRMocAmpZ5EVuPbfCFgPycs24rGjxy3GMxrcM8hjkcdbxeECedaQnDWjH_4jeIPc7AsTZrj9Up1-yVm0zZxC6VygEspTOCQhutI24DU7mEffRgGytzy5rlX-Z_RXVAXnaLYPa4luMLX21qmlUJLH29wIaFSstIUGF_-ieXPQ23V8pj7_WIOGQuAud8AcXb_AJuQZalL2f7u0-JNcF1usg3K_ZIpsgMP4RBFxn-eNasin5fNmq9AccE0Ot
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+Seroprevalence+Structure+of+the+Russian+Population+during+the+COVID-19+Pandemic&rft.jtitle=Viruses&rft.au=Anna+Y.+Popova&rft.au=Viacheslav+S.+Smirnov&rft.au=Elena+E.+Andreeva&rft.au=Elena+A.+Babura&rft.date=2021-08-19&rft.pub=MDPI+AG&rft.eissn=1999-4915&rft.volume=13&rft.issue=8&rft.spage=1648&rft_id=info:doi/10.3390%2Fv13081648&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d9653926ac204dd28537a01afd4b01e0
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon